Anteris Technologies to Present DurAVR Data at TCT 2026
The company will showcase new clinical and hemodynamic outcomes for its heart valve system at the upcoming medical conference.
Updated on Oct. 27, 2026 in Heart Disease
Live Poll
Do you believe new biomimetic heart valve technologies will improve long-term outcomes for aortic stenosis patients?
Anteris Technologies will present clinical data for its DurAVR THV system at the TCT 2026 conference in San Diego. The presentations scheduled for November 1 and November 3 will highlight performance outcomes from the company's ongoing study programs.
Why it matters
Sharing clinical outcomes at major industry events provides the medical community with critical performance data on emerging cardiovascular technologies. This transparency is essential for clinicians evaluating new treatment options for patients with structural heart conditions.
Over 130 patients have participated in the EMBARK and Early Feasibility Study clinical trials since 2021. The underlying ADAPT tissue technology used in the DurAVR THV has been applied clinically for over 10 years across 55,000 patients globally.
The players
Anteris Technologies
Anteris Technologies is a medical device company that develops advanced valve systems for structural heart disease treatment.
Azeem Latib
Azeem Latib is a medical professional scheduled to present 30-day clinical and hemodynamic outcomes at the TCT conference.
Santiago Garcia
Santiago Garcia is a medical professional who will present on the DurAVR technology and conduct a case-in-a-box session.
The details
The DurAVR THV system integrates a specific valve design, ADAPT tissue technology, and the ComASUR Delivery System to address patient needs. Presentations during the conference will cover 30-day hemodynamic outcomes for medium-size valves as well as a technical case-in-a-box session.
Timeline
The TCT 2026 conference is scheduled for October 31 to November 3, 2026.
Azeem Latib will present clinical and hemodynamic results on November 1, 2026.
Santiago Garcia will lead a session on the valve technology on November 3, 2026.
Health Landscape
The TCT conference serves as a pivotal forum for the release of clinical data in the cardiovascular field. Anteris Technologies aligns its latest trial findings with this established scientific platform to share developments in valve technology with a global audience of peers.
Patients and healthcare providers can monitor these results to better understand the potential performance and safety of new transcatheter heart valve systems. These clinical milestones represent incremental steps toward the eventual regulatory review and availability of new treatment options.
The takeaway
Advancements in valve technology like those presented at TCT depend on sustained long-term testing and iterative clinical feedback. Clinicians and patients should focus on peer-reviewed trial outcomes when evaluating the suitability of these evolving technologies for individual health needs.
Further reading
Learn more about the latest advancements in the field by visiting our Heart Disease section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe new biomimetic heart valve technologies will improve long-term outcomes for aortic stenosis patients?
